Gladstone Investment (GAIN) is rated a buy due to its impressive long-term returns, with 5- and 10-year total returns of 103% and 444%, respectively. Its strategy focuses on private equity-led buyouts, resulting in significant equity appreciation. However, the portfolio is highly concentrated, with five companies making up 44.5% of its value, which increases risk. The portfolio's mix of equity and preferred equity drives growth but also exposes investors to valuation risks. Investors should carefully consider position sizing due to this concentration risk.
Gladstone Investment (GAIN) is noted for its long-term returns, achieving 103% over 5 years and 444% over 10 years. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 21, 2026 13:41 WIB: out of 142 priced US Financials stocks, 121 rose and 17 fell today. Notable movers include CRCL at USD 85.78 with a 5.42% increase and 100% buy order activity, MSCI at USD 596.45 with a 5.28% rise but 92% sell order activity, and RKT at USD 11.26 with a 5.14% gain and 100% buy order activity.
A webinar titled "Ready for AI?" scheduled for October 29, 2026, will discuss how artificial intelligence is reshaping public relations by changing how information is found, evaluated, and shared. Experts will share insights on maintaining message vi...
17a-4 LLC introduced DataParser Hub, an API that enables clients to integrate proprietary messaging and collaboration data into Microsoft 365 Purview and Copilot. This solution supports over 30 data types from platforms like Slack, Zoom, and Webex, a...
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...
